Cardiovascular Today—Februrary 5, 2026

LucidQuest

4 hours ago

This is the weekly update in cardiovascular medicine, summarizing key developments such as regulatory actions, clinical trial progress, partnerships, and important data releases.

In Today’s Newsletter

Dive deeper

💊 GE HealthCare’s Allia Moveo gains FDA and CE mark approvals [1] [3 February 2026]

https://investor.gehealthcare.com/news-releases/news-release-details/ge-healthcare-announces-us-fda-510k-clearance-and-ce-mark-allia
Context: GE HealthCare’s Allia Moveo image-guidance platform receives FDA 510(k) clearance and CE mark.
Key point: Allia Moveo enables a compact, cable-free C-arm system with AI-powered guidance, supporting cardiovascular and interventional procedures.
Implication: Enhanced image-guidance systems will improve workflow and control during procedures, potentially influencing clinic adoption and cost assessments.

🧪 Endospan announces one-year data from TRIOMPHE IDE study [2] [3 February 2026]

https://cardiovascularnews.com/endospan-announces-one-year-data-from-triomphe-ide-study/
Context: TRIOMPHE IDE study on Endospan’s Nexus aortic arch stent graft reports promising one-year results.
Key point: The Nexus system shows low stroke and mortality rates in high-risk aortic arch patients.
Implication: This could lead to broader acceptance of the Nexus system for treating complex aortic conditions, pending FDA approval.

🧠 Medtronic exercises its option to acquire CathWorks [3] [3 February 2026]

https://cardiovascularnews.com/medtronic-exercises-its-option-to-acquire-cathworks/
Context: Medtronic announces plans to acquire CathWorks, following a co-promotion agreement for the FFRangio system.
Key point: The acquisition, valued at up to $585 million, aims to revolutionize coronary diagnostics with AI-powered technology.
Implication: This deal may influence the market for coronary physiology assessments, offering a new tool for clinicians and potentially improving patient outcomes.

🤝 STS 2026: Long-term comparison of multi-arterial CABG strategies finds similar survival rates [4] [3 February 2026]

https://cardiovascularnews.com/sts-2026-long-term-comparison-of-multi-arterial-cabg-strategies-finds-similar-survival-rates/
Context: Multi-arterial CABG strategies, BITA and SITA+RA, provide similar long-term survival, with slight differences based on patient age.
Key point: BITA shows modest advantage in younger patients, while SITA+RA is slightly better in older patients.
Implication: The findings may influence CABG treatment decisions and guide personalized patient care based on age and risk factors.

🫀 LUMC and Ncardia accelerate drug research with mini-heart model [5] [2 February 2026]

https://bioprocessingnews.nl/news/lumc-and-ncardia-accelerate-drug-research-with-mini-heart-model
Context: LUMC and Ncardia use mini-heart models to test drugs for congenital heart rhythm disorders.
Key point: The technology, based on stem cells, allows for faster and more accurate drug testing in a high-risk patient population.
Implication: This platform could significantly shorten the timeline for drug development in rare cardiovascular diseases.

🧬 Clinical trial offers first-of-its-kind heart failure treatment [6] [2 February 2026]

https://health.ucdavis.edu/news/headlines/clinical-trial-offers-first-of-its-kind-heart-failure-treatment/2026/02
Context: UC Davis Health launches a clinical trial for a minimally invasive heart failure treatment that improves symptoms by reducing pressure in the heart.
Key point: The procedure involves a catheter-based method to reduce left atrial pressure, offering an innovative option for heart failure patients.
Implication: This trial could pave the way for new, less invasive treatments for heart failure, expanding options for patients who are not responding to traditional therapies.

🧯 Brainomix launches next-generation stroke AI platform [7] [2 February 2026]

Brainomix Launches Next Generation Stroke AI Platform | DAIC
Context: Brainomix unveils the Brainomix 360 Next Generation AI platform for stroke imaging, incorporating net water uptake for improved stroke assessment.
Key point: The new platform utilizes routine non-contrast CT scans to deliver enhanced imaging capabilities for stroke treatment decisions.
Implication: The AI system could streamline stroke care, potentially improving patient outcomes by allowing for faster and more accurate diagnosis and decision-making.

💉 Nasal spray for paroxysmal supraventricular tachycardia enters US market [8] [2 February 2026]

https://cardiovascularbusiness.com/topics/clinical/heart-rhythm/nasal-spray-paroxysmal-supraventricular-tachycardia-enters-us-market
Context: Etripamil nasal spray, approved by the FDA, is now available in the US to treat PSVT episodes at home.
Key point: This first-of-its-kind nasal spray offers a non-invasive treatment for managing paroxysmal supraventricular tachycardia at home.
Implication: The launch could reduce emergency department visits and improve quality of life for PSVT patients, particularly those who are injection-averse.

🏥 Allegheny Health Network opens first heart clinic focused on South Asian patient population [9] [3 February 2026]

https://www.prnewswire.com/news-releases/allegheny-health-network-opens-first-heart-clinic-in-pennsylvania-focused-on-addressing-critical-health-disparities-among-south-asian-patient-population-302677771.html
Context: AHN opens a specialized clinic in Pennsylvania for South Asian patients, focusing on early detection and prevention of heart disease.
Key point: The clinic addresses elevated cardiovascular risk in South Asians, who face a fourfold higher risk of heart disease compared to the general population.
Implication: This initiative could set a precedent for targeted, culturally sensitive healthcare models to address health disparities in diverse communities.

Why it matters

New imaging and AI tools in cardiovascular care continue to refine treatment and diagnosis, offering more precise and personalized approaches.
Minimally invasive treatments for heart failure and PSVT represent an evolving trend towards reducing the burden on patients and healthcare systems.
Specialized clinics like AHN’s South Asian Heart Clinic will help address disparities and improve heart health outcomes in at-risk populations.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 See the full Cardiovascular archive on our research hub page

FAQ

What is the significance of GE HealthCare’s Allia Moveo approval?

The Allia Moveo system’s FDA and CE mark approvals bring a high-performance image-guidance platform to interventional procedures, improving workflow and clinical outcomes.

What are the benefits of Endospan’s Nexus system in the TRIOMPHE study?

The Nexus aortic arch stent graft has shown promising one-year results, demonstrating low stroke and mortality rates in high-risk patients, making it a potential breakthrough in treating complex aortic conditions.

How does Brainomix’s new AI platform improve stroke care?

Brainomix’s new platform utilizes net water uptake from non-contrast CT scans to provide clinicians with enhanced imaging for better stroke treatment decisions, streamlining diagnosis and care.

Entities / Keywords

GE HealthCare, Allia Moveo, Nexus system, Medtronic, CathWorks, FFRangio, UC Davis Health, Brainomix, stroke AI, paroxysmal supraventricular tachycardia, Allegheny Health Network, South Asian heart health, PSVT, coronary care.